Eric H. Yang, MD

Eric Yang, MD


Associate Clinical Professor of Medicine, Department of Medicine/Cardiology





Cardiovascular Disease, Harbor - UCLA Medical Center, 2011


Internal Medicine, Harbor - UCLA Medical Center, 2006


MD, University of Illinois at Chicago, Chicago, IL, 2005
BS, University of Illinois at Chicago, Chicago, IL, 2001
BA, University of Illinois at Chicago, Chicago, IL, 2001


Internal Medicine Residency, Harbor-UCLA Medical Center
Cardiovascular Disease Residency, Harbor-UCLA Medical Center

Board Certifications

Cardiovascular Disease, American Board of Internal Medicine, 2011
Internal Medicine, American Board of Internal Medicine, 2008

Scientific Interests

As the Director and Founder of the UCLA Cardio-Oncology Program, Dr. Yang's clinical and research interests have been focused on the elucidation of the mechanistic overlap between cardiovascular disease and cardiotoxicity induced by both historical and more modern novel cancer treatments. He currently balance an active clinical practice in providing timely care, cardiovascular risk stratification, and cardiotoxicity diagnosis/treatment of the cancer population of UCLA Health, and also conduct clinical research in 1) defining clinical characteristics of patients who develop cardiotoxicity in all cancer disease statements and/or treatments, and 2) formulate cardioprotective strategies in detecting, and attenuating subclinical cardiotoxicity.

Highlighted Publications

Vascular Toxicities of Cancer Therapies: The Old and The New—An Evolving Avenue. Joerg Herrmann, Eric H Yang, Cezar Iliescu, Cindy Grines, Mehmet Cilingiroglu, Kostantinos Charitakis, Abdul Hakeem, Konstantinos Toutouzas, Massoud A Lessar, Konstantinos Marmagkiolis. Circulation. 133(13):1272-89.doi:10.1161/CIRCULATIONAHA.115.018347. 2016.

Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the american heart association COVID-19 cardiovascular disease registry. David M Tehrani, Xiaoyan Wang, Asim M Rafique, Salim S Hayek, Joerg Herrmann, Tomas G Neilan, Pooja Desai, Alicia Morgans, Juan Lopez-Mattei, Rushi V Parikh, Eric H Yang. Cardio-Oncology 2021;7, 28.

Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. Ohad Oren, Eric H Yang, Julian R Molina, Kent R Bailey, Roger S Blumenthal, Stephen L Kopecky. Am J Card 2020 pii: S0002-9149(20)30186-7. doi: 10.1016/j.amjcard.2020.02.016.

Cardiovascular Magnetic Resonance in Immune Checkpoint Inhibitor-Associated Myocarditis. Lily Zhang, Magid Awadalla, Syed S Mahmood...Eric H Yang, et al. Eur Heart J 2020; pii: ehaa051. doi: 10.1093/eurheartj/ehaa051.

Cardiotoxicities of Novel Cancer Immunotherapies. Ashley F Stein-Merlob, Michael V Rothberg, Antoni Ribas, Eric H Yang. Heart. 2021 Mar 15:heartjnl-2020-318083. doi: 10.1136/heartjnl-2020-318083.